XML 36 R18.htm IDEA: XBRL DOCUMENT
v3.22.1

Segments of Business and Geographic Areas | 3 Months Ended
--- | ---
Apr. 03, 2022
Segment Reporting [Abstract] |
Segments of Business and Geographic Areas | SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | Percent Change |  |  |  |  |  |
CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  |
OTC(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 670 |  |  | 599 |  |  | 11.8 | % |  |  |  |  |  |
International |  | 791 |  |  | 673 |  |  | 17.5 |  |  |  |  |  |  |
Worldwide |  | 1,461 |  |  | 1,273 |  |  | 14.8 |  |  |  |  |  |  |
Skin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 544 |  |  | 634 |  |  | (14.2) |  |  |  |  |  |  |
International |  | 468 |  |  | 529 |  |  | (11.6) |  |  |  |  |  |  |
Worldwide |  | 1,012 |  |  | 1,163 |  |  | (13.0) |  |  |  |  |  |  |
Oral Care |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 143 |  |  | 163 |  |  | (12.6) |  |  |  |  |  |  |
International |  | 223 |  |  | 254 |  |  | (12.0) |  |  |  |  |  |  |
Worldwide |  | 366 |  |  | 417 |  |  | (12.2) |  |  |  |  |  |  |
Baby Care |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 85 |  |  | 96 |  |  | (11.5) |  |  |  |  |  |  |
International |  | 270 |  |  | 293 |  |  | (7.7) |  |  |  |  |  |  |
Worldwide |  | 355 |  |  | 389 |  |  | (8.6) |  |  |  |  |  |  |
Women's Health |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  |  | 3 |  |  | 7.2 |  |  |  |  |  |  |
International |  | 224 |  |  | 219 |  |  | 2.5 |  |  |  |  |  |  |
Worldwide |  | 228 |  |  | 222 |  |  | 2.6 |  |  |  |  |  |  |
Wound Care/Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 112 |  |  | 115 |  |  | (3.3) |  |  |  |  |  |  |
International |  | 52 |  |  | 61 |  |  | (15.3) |  |  |  |  |  |  |
Worldwide |  | 164 |  |  | 177 |  |  | (7.4) |  |  |  |  |  |  |
TOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,557 |  |  | 1,611 |  |  | (3.4) |  |  |  |  |  |  |
International |  | 2,029 |  |  | 2,030 |  |  | 0.0 |  |  |  |  |  |
Worldwide |  | 3,586 |  |  | 3,641 |  |  | (1.5) |  |  |  |  |  |  |
PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,501 |  |  | 2,413 |  |  | 3.7 |  |  |  |  |  |  |
International |  | 1,617 |  |  | 1,501 |  |  | 7.7 |  |  |  |  |  |  |
Worldwide |  | 4,119 |  |  | 3,914 |  |  | 5.2 |  |  |  |  |  |  |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 358 |  |  | 489 |  |  | (26.8) |  |  |  |  |  |  |
U.S. Exports |  | 80 |  |  | 57 |  |  | 40.5 |  |  |  |  |  |  |
International |  | 225 |  |  | 232 |  |  | (2.6) |  |  |  |  |  |  |
Worldwide |  | 663 |  |  | 777 |  |  | (14.7) |  |  |  |  |  |  |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 287 |  |  | 255 |  |  | 12.5 |  |  |  |  |  |  |
International |  | 283 |  |  | 307 |  |  | (7.6) |  |  |  |  |  |  |
Worldwide |  | 571 |  |  | 562 |  |  | 1.5 |  |  |  |  |  |  |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,379 |  |  | 1,331 |  |  | 3.6 |  |  |  |  |  |  |
International |  | 909 |  |  | 817 |  |  | 11.2 |  |  |  |  |  |  |
Worldwide |  | 2,288 |  |  | 2,148 |  |  | 6.5 |  |  |  |  |  |  |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 391 |  |  | 274 |  |  | 42.7 |  |  |  |  |  |  |
International |  | 199 |  |  | 143 |  |  | 38.8 |  |  |  |  |  |  |
Worldwide |  | 590 |  |  | 418 |  |  | 41.3 |  |  |  |  |  |  |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 6 |  |  | 7 |  |  | (3.2) |  |  |  |  |  |  |
International |  | 0 |  |  | 2 |  |  | * |  |  |  |  |  |
Worldwide |  | 6 |  |  | 8 |  |  | (22.0) |  |  |  |  |  |  |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 461 |  |  | 512 |  |  | (10.0) |  |  |  |  |  |  |
International |  | 836 |  |  | 485 |  |  | 72.3 |  |  |  |  |  |  |
Worldwide |  | 1,297 |  |  | 998 |  |  | 30.0 |  |  |  |  |  |  |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 75 |  |  | 100 |  |  | (24.9) |  |  |  |  |  |  |
International |  | 382 |  |  | 0 |  | * |  |  |  |  |  |
Worldwide |  | 457 |  |  | 100 |  |  | * |  |  |  |  |  |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 9 |  |  | 10 |  |  | (12.6) |  |  |  |  |  |  |
International |  | 239 |  |  | 233 |  |  | 2.5 |  |  |  |  |  |  |
Worldwide |  | 248 |  |  | 243 |  |  | 1.8 |  |  |  |  |  |  |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 369 |  |  | 380 |  |  | (3.1) |  |  |  |  |  |  |
International |  | 132 |  |  | 166 |  |  | (20.3) |  |  |  |  |  |  |
Worldwide |  | 501 |  |  | 546 |  |  | (8.3) |  |  |  |  |  |  |
OTHER INFECTIOUS DISEASES(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 8 |  |  | 21 |  |  | (62.5) |  |  |  |  |  |  |
International |  | 83 |  |  | 87 |  |  | (3.8) |  |  |  |  |  |  |
Worldwide |  | 91 |  |  | 108 |  |  | (15.3) |  |  |  |  |  |  |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 843 |  |  | 771 |  |  | 9.3 |  |  |  |  |  |  |
International |  | 898 |  |  | 943 |  |  | (4.8) |  |  |  |  |  |  |
Worldwide |  | 1,741 |  |  | 1,715 |  |  | 1.5 |  |  |  |  |  |  |
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 35 |  |  | 47 |  |  | (26.5) |  |  |  |  |  |  |
International |  | 122 |  |  | 123 |  |  | (1.3) |  |  |  |  |  |  |
Worldwide |  | 157 |  |  | 171 |  |  | (8.3) |  |  |  |  |  |  |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 661 |  |  | 589 |  |  | 12.2 |  |  |  |  |  |  |
International |  | 387 |  |  | 376 |  |  | 3.0 |  |  |  |  |  |  |
Worldwide |  | 1,048 |  |  | 965 |  |  | 8.6 |  |  |  |  |  |  |
RISPERDAL CONSTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 63 |  |  | 67 |  |  | (6.4) |  |  |  |  |  |  |
International |  | 66 |  |  | 89 |  |  | (26.1) |  |  |  |  |  |  |
Worldwide |  | 129 |  |  | 157 |  |  | (17.6) |  |  |  |  |  |  |
OTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 84 |  |  | 67 |  |  | 25.5 |  |  |  |  |  |  |
International |  | 323 |  |  | 355 |  |  | (8.9) |  |  |  |  |  |  |
Worldwide |  | 408 |  |  | 422 |  |  | (3.5) |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,582 |  |  | 1,377 |  |  | 14.9 |  |  |  |  |  |  |
International |  | 2,369 |  |  | 2,193 |  |  | 8.0 |  |  |  |  |  |  |
Worldwide |  | 3,950 |  |  | 3,570 |  |  | 10.6 |  |  |  |  |  |  |
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 953 |  |  | 691 |  |  | 37.9 |  |  |  |  |  |  |
International |  | 903 |  |  | 674 |  |  | 34.0 |  |  |  |  |  |  |
Worldwide |  | 1,856 |  |  | 1,365 |  |  | 36.0 |  |  |  |  |  |  |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 206 |  |  | 171 |  |  | 20.3 |  |  |  |  |  |  |
International |  | 194 |  |  | 90 |  |  | * |  |  |  |  |  |
Worldwide |  | 400 |  |  | 261 |  |  | 53.0 |  |  |  |  |  |  |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 370 |  |  | 444 |  |  | (16.7) |  |  |  |  |  |  |
International |  | 668 |  |  | 680 |  |  | (1.8) |  |  |  |  |  |  |
Worldwide |  | 1,038 |  |  | 1,125 |  |  | (7.7) |  |  |  |  |  |  |
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 19 |  |  | 50 |  |  | (62.1) |  |  |  |  |  |  |
International |  | 520 |  |  | 588 |  |  | (11.6) |  |  |  |  |  |  |
Worldwide |  | 539 |  |  | 638 |  |  | (15.6) |  |  |  |  |  |  |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 34 |  |  | 21 |  |  | 63.1 |  |  |  |  |  |  |
International |  | 84 |  |  | 161 |  |  | (47.7) |  |  |  |  |  |  |
Worldwide |  | 118 |  |  | 182 |  |  | (35.1) |  |  |  |  |  |  |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 572 |  |  | 573 |  |  | (0.2) |  |  |  |  |  |  |
International |  | 279 |  |  | 288 |  |  | (2.9) |  |  |  |  |  |  |
Worldwide |  | 852 |  |  | 861 |  |  | (1.1) |  |  |  |  |  |  |
OPSUMIT |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 273 |  |  | 272 |  |  | 0.5 |  |  |  |  |  |  |
International |  | 170 |  |  | 179 |  |  | (4.8) |  |  |  |  |  |  |
Worldwide |  | 443 |  |  | 450 |  |  | (1.6) |  |  |  |  |  |  |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 269 |  |  | 259 |  |  | 3.9 |  |  |  |  |  |  |
International |  | 56 |  |  | 46 |  |  | 20.9 |  |  |  |  |  |  |
Worldwide |  | 325 |  |  | 305 |  |  | 6.5 |  |  |  |  |  |  |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 30 |  |  | 42 |  |  | (29.0) |  |  |  |  |  |  |
International |  | 53 |  |  | 63 |  |  | (15.2) |  |  |  |  |  |  |
Worldwide |  | 83 |  |  | 105 |  |  | (20.8) |  |  |  |  |  |  |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 672 |  |  | 799 |  |  | (15.8) |  |  |  |  |  |  |
International |  | 238 |  |  | 245 |  |  | (3.0) |  |  |  |  |  |  |
Worldwide |  | 910 |  |  | 1,044 |  |  | (12.8) |  |  |  |  |  |  |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  |
International |  | — |  |  | — |  |  | — |  |  |  |  |  |  |
Worldwide |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  |
INVOKANA / INVOKAMET |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 60 |  |  | 87 |  |  | (30.7) |  |  |  |  |  |  |
International |  | 68 |  |  | 63 |  |  | 7.5 |  |  |  |  |  |  |
Worldwide |  | 128 |  |  | 150 |  |  | (14.6) |  |  |  |  |  |  |
OTHER(1,2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 104 |  |  | 122 |  |  | (14.9) |  |  |  |  |  |  |
International |  | 170 |  |  | 182 |  |  | (6.6) |  |  |  |  |  |  |
Worldwide |  | 274 |  |  | 305 |  |  | (10.0) |  |  |  |  |  |  |
TOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 6,632 |  |  | 6,446 |  |  | 2.9 |  |  |  |  |  |  |
International |  | 6,237 |  |  | 5,655 |  |  | 10.3 |  |  |  |  |  |  |
Worldwide |  | 12,869 |  |  | 12,101 |  |  | 6.3 |  |  |  |  |  |  |
MEDTECH(3) |  |  |  |  |  |  |  |  |  |  |  |
Interventional Solutions |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 494 |  |  | 434 |  |  | 13.8 |  |  |  |  |  |  |
International |  | 597 |  |  | 514 |  |  | 16.2 |  |  |  |  |  |  |
Worldwide |  | 1,092 |  |  | 949 |  |  | 15.1 |  |  |  |  |  |  |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,289 |  |  | 1,249 |  |  | 3.2 |  |  |  |  |  |  |
International |  | 899 |  |  | 864 |  |  | 4.1 |  |  |  |  |  |  |
Worldwide |  | 2,188 |  |  | 2,113 |  |  | 3.5 |  |  |  |  |  |  |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 225 |  |  | 209 |  |  | 7.3 |  |  |  |  |  |  |
International |  | 164 |  |  | 146 |  |  | 12.2 |  |  |  |  |  |  |
Worldwide |  | 389 |  |  | 356 |  |  | 9.3 |  |  |  |  |  |  |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 201 |  |  | 185 |  |  | 8.6 |  |  |  |  |  |  |
International |  | 138 |  |  | 132 |  |  | 4.1 |  |  |  |  |  |  |
Worldwide |  | 339 |  |  | 317 |  |  | 6.7 |  |  |  |  |  |  |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 475 |  |  | 450 |  |  | 5.5 |  |  |  |  |  |  |
International |  | 273 |  |  | 282 |  |  | (3.3) |  |  |  |  |  |  |
Worldwide |  | 748 |  |  | 733 |  |  | 2.1 |  |  |  |  |  |  |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 387 |  |  | 404 |  |  | (4.1) |  |  |  |  |  |  |
International |  | 324 |  |  | 303 |  |  | 7.0 |  |  |  |  |  |  |
Worldwide |  | 712 |  |  | 707 |  |  | 0.6 |  |  |  |  |  |  |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 921 |  |  | 898 |  |  | 2.5 |  |  |  |  |  |  |
International |  | 1,513 |  |  | 1,474 |  |  | 2.7 |  |  |  |  |  |  |
Worldwide |  | 2,434 |  |  | 2,372 |  |  | 2.6 |  |  |  |  |  |  |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 417 |  |  | 405 |  |  | 3.0 |  |  |  |  |  |  |
International |  | 729 |  |  | 713 |  |  | 2.2 |  |  |  |  |  |  |
Worldwide |  | 1,146 |  |  | 1,118 |  |  | 2.5 |  |  |  |  |  |  |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 504 |  |  | 493 |  |  | 2.1 |  |  |  |  |  |  |
International |  | 784 |  |  | 761 |  |  | 3.1 |  |  |  |  |  |  |
Worldwide |  | 1,288 |  |  | 1,254 |  |  | 2.7 |  |  |  |  |  |  |
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 521 |  |  | 472 |  |  | 10.4 |  |  |  |  |  |  |
International |  | 736 |  |  | 673 |  |  | 9.4 |  |  |  |  |  |  |
Worldwide |  | 1,257 |  |  | 1,145 |  |  | 9.8 |  |  |  |  |  |  |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 400 |  |  | 371 |  |  | 7.7 |  |  |  |  |  |  |
International |  | 511 |  |  | 486 |  |  | 5.1 |  |  |  |  |  |  |
Worldwide |  | 910 |  |  | 857 |  |  | 6.2 |  |  |  |  |  |  |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 121 |  |  | 101 |  |  | 20.2 |  |  |  |  |  |  |
International |  | 226 |  |  | 187 |  |  | 20.5 |  |  |  |  |  |  |
Worldwide |  | 347 |  |  | 288 |  |  | 20.4 |  |  |  |  |  |  |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,225 |  |  | 3,054 |  |  | 5.6 |  |  |  |  |  |  |
International |  | 3,746 |  |  | 3,525 |  |  | 6.3 |  |  |  |  |  |  |
Worldwide |  | 6,971 |  |  | 6,579 |  |  | 5.9 |  |  |  |  |  |  |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 11,414 |  |  | 11,111 |  |  | 2.7 |  |  |  |  |  |  |
International |  | 12,012 |  |  | 11,210 |  |  | 7.2 |  |  |  |  |  |  |
Worldwide |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |
*Percentage greater than 100% or not meaningful (1) In the fiscal first quarter of 2021, approximately $0.1 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (2) Inclusive of PROCRIT / EPREX which was previously disclosed separately (3) Previously referred to as Medical Devices EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*
|  | Fiscal First Quarter Ended |  |  |
(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | Percent Change |  |  |  |  |  |  |  |  |  |  |
Consumer Health (1) |  | $ | 686 |  |  | 842 |  |  | (18.5)% |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical(2) |  | 3,924 |  |  | 5,169 |  |  | (24.1) |  |  |  |  |  |  |  |  |  |  |
MedTech(3) |  | 1,477 |  |  | 1,629 |  |  | (9.3) |  |  |  |  |  |  |  |  |  |  |
Segment earnings before provision for taxes |  | 6,087 |  |  | 7,640 |  |  | (20.3) |  |  |  |  |  |  |  |  |  |  |
Less: Expense not allocated to segments (4) |  | 123 |  |  | 211 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less: Consumer Health separation costs |  | 102 |  |  | — |  |  |  |  |  |  |  |  |  |  |  |  |  |
Worldwide income before tax |  | $ | 5,862 |  |  | 7,429 |  |  | (21.1)% |  |  |  |  |  |  |  |  |  |  |
*Fiscal first quarter 2021 earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (1) Consumer Health includes: •Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2022 and 2021 (2) Pharmaceutical includes: •Divestiture gains of $0.6 billion in the fiscal first quarter of 2021 related to two brands outside the U.S. •Intangible amortization expense of $0.8 billion and $0.9 billion in the fiscal first quarter of 2022 and 2021, respectively •In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. •A loss of $0.4 billion related to the change in the fair value of securities in the fiscal first quarter of 2022 In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply. (3) MedTech includes: •A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2022 and 2021 •Intangible amortization expense of $0.3 billion in both the fiscal first quarter of 2022 and 2021 (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | Percent Change |  |  |  |  |  |
United States |  | $ | 11,414 |  |  | 11,111 |  |  | 2.7 | % |  |  |  |  |  |
Europe |  | 6,024 |  |  | 5,414 |  |  | 11.3 |  |  |  |  |  |  |
Western Hemisphere, excluding U.S. |  | 1,482 |  |  | 1,424 |  |  | 4.1 |  |  |  |  |  |  |
Asia-Pacific, Africa |  | 4,506 |  |  | 4,372 |  |  | 3.1 |  |  |  |  |  |  |
Total |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration